

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Packet Meeting – August 14, 2024

NOTE: ***No live August meeting. August 2024 is a packet-only meeting.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. DUR Board Meeting Minutes – See Appendix A

- A. July 10, 2024 DUR Board Meeting Minutes
- B. July 10, 2024 DUR Board Recommendations Memorandum

Items to be presented by Dr. Wilson, Dr. Moss, Dr. Muchmore, Chairman:

2. Update on Medication Coverage Authorization Unit/U.S. Food and Drug Administration (FDA) Safety Alerts – See Appendix B

- A. Pharmacy Help Desk Activity for July 2024
- B. Medication Coverage Activity for July 2024
- C. FDA Safety Alerts

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

3. Annual Review of Wilson's Disease Medications and 30-Day Notice to Prior Authorize Penicillamine 250mg Tablet and Trientine Hydrochloride 500mg Capsule – See Appendix C

- A. Current Prior Authorization Criteria
- B. Utilization of Wilson's Disease Medications
- C. Prior Authorization of Wilson's Disease Medications
- D. Market News and Updates
- E. Cost Comparisons
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

4. Annual Review of Corticosteroid Special Formulations and 30-Day Notice to Prior Authorize Eohilia™ (Budesonide Oral Suspension) – See Appendix D

- A. Current Prior Authorization Criteria
- B. Utilization of Corticosteroid Special Formulations
- C. Prior Authorization of Corticosteroid Special Formulations
- D. Market News and Updates
- E. Eohilia™ (Budesonide Oral Suspension) Product Summary
- F. Cost Comparison
- G. College of Pharmacy Recommendations
- H. Utilization Details of Corticosteroid Special Formulations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

5. Annual Review of Iron Products and 30-Day Notice to Prior Authorize Accrufer® (Ferric Maltol) – See Appendix E

- A. Current Prior Authorization Criteria
- B. Utilization of Iron Products
- C. Prior Authorization of Iron Products
- D. Market News and Updates
- E. Accrufer® (Ferric Maltol) Product Summary
- F. Cost Comparison: Intravenous (IV) Iron Products
- G. College of Pharmacy Recommendations
- H. Utilization Details of Iron Products

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

6. Annual Review of Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications and 30-Day Notice to Prior Authorize Tramadol 25mg Tablet – See Appendix F

- A. Current Prior Authorization Criteria
- B. Utilization of Opioid Analgesics and MAT Medications
- C. Prior Authorization of Opioid Analgesics and MAT Medications
- D. Market News and Updates
- E. Cost Comparison: Tramadol
- F. College of Pharmacy Recommendations
- G. Utilization Details of Opioid Analgesics and MAT Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

7. Annual Review of Topical Corticosteroids – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization of Topical Corticosteroids
- C. Prior Authorization of Topical Corticosteroids
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Topical Corticosteroids

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

8. Annual Review of Various Systemic Antibiotics and 30-Day Notice to Prior Authorize Doryx® MPC [Doxycycline Delayed-Release (DR) Tablet], Exblifep® (Cefepime/Enmetazobactam), Meropenem 2g Vial, Pivya™ (Pivmecillinam), Nitrofurantoin 50mg/mL Suspension, Tetracycline 250mg and 500mg Tablet, Zevtera® (Ceftobiprole Medocaril Sodium) – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Various Systemic Antibiotics
- C. Prior Authorization of Various Systemic Antibiotics
- D. Market News and Updates

- E. Product Summaries
- F. Cost Comparisons
- G. College of Pharmacy Recommendations
- H. Utilization Details of Various Systemic Antibiotics

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

9. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix I

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

10. Future Business* (Upcoming Product and Class Reviews)

- A. Allergen Immunotherapies
- B. Amyloidosis Medications
- C. Breast Cancer Medications
- D. Cystic Fibrosis Medications

*Future product and class reviews subject to change.

11. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.